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Cysticﬁbrosis(CF)isanautosomalrecessivediseasethatmaybecausedbymorethan1000diﬀerentmutationsinthecysticﬁbrosis
transmembrane conductance regulator (CFTR) gene. We describe the case of a CF patient who was initially diagnosed at 16 years
of age after presenting with mild respiratory compromise and pancreatic suﬃciency. When genetic testing was ﬁrst performed
using a CF mutation panel, only a single F508del CFTR allele was identiﬁed. We subsequently performed testing, which revealed a
previously unreported mutation: A457P (p.Ala457Pro, c.1369G>C). The patient’s clinical course through adulthood is described,
and genotype-phenotype correlation is discussed. The A457P mutation appears to confer a relatively mild phenotype, as is usually
observed with CFTR class IV–VI defects. With the advent of more comprehensive and widely available genetic testing techniques,
identiﬁcation of CF genotypes in patients with milder disease variants may help stratify patients for targeted therapy and prevent
late complications of the disease.
1.Introduction
The median age of diagnosis of cystic ﬁbrosis is 6 months,
although it is increasingly common for patients to be diag-
nosed as adults [1, 2]. The majority of aﬀected patients iden-
tiﬁed early in life (nearly 90% in the USA) have at least one
copyoftheF508delmutation,andheterozygotesusuallyhave
a second allele that is identiﬁed on appropriate mutation
panels [3]. However, individuals who are diagnosed later in
life are more likely to have mild disease, often associated
with CFTR mutations that confer less protein dysfunction
and may not be detected on standard, commerciallyavailable
assays [4, 5]. We describe a patient, diagnosed with CF at age
16 years, who had one F508del mutation and an unidentiﬁed
allele on standard genetic testing using a CF mutation
screening panel. After transfer of care to our institution,
a full-sequence CFTR genetic analysis was performed by
Ambry Genetics, which revealed an A457P mutation in
combination with the F508 deletion. We brieﬂy describe
the clinical proﬁle of this patient with the A457P mutation,
discusstheestablishedcriteriausedtodiagnoseCF,andspec-
ulate about the possibility that this newly identiﬁed vari–
ant is a disease-causing mutation.
2. Case Presentation
A 35-year-old Caucasian male presented to the adult cystic
ﬁbrosis program at our institution in 2002. He was initially
diagnosed with CF at the age of 16 years after evaluation
for persistent cough and recurrent bouts of bronchitis. Sweat
chloride concentration was 79mmol/L and 86mmol/L on
subsequent testing. At the time of diagnosis he had never
been admitted to the hospital for respiratory infections. He
produced about a tablespoon of sputum daily. Sputum cul-
tures frequently grew StaphylococcusaureusandHaemophilus
inﬂuenzaandoccasionallyPseudomonasaeruginosa.Utilizing
a commercially available CFTR mutation panel, testing
at that time showed only a single copy of the F508del
mutation while the second allele remained unidentiﬁed.
Childhood history was notable only for tonsillectomy. He2 Case Reports in Medicine
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Figure 1: Chest roentgenogram at 35 years of age shows hyperinﬂation and increased linear markings particularly in the right lower lung
zones and perihilar regions corresponding to a Brasﬁeld et al. score of 15 [6].
had no problems maintaining weight nor did he suﬀer from
steatorrhea. Both of his parents came from British and
Scottish backgrounds. One maternal cousin’s daughter was
diagnosed with clinical CF. At the time of presentation to our
institution, he worked as a teacher at a local university and
was completing his doctoral thesis in musicology. As part of
his studies, he played wind instruments, and he reported no
diﬃculty with these exercises.
On examination at our institution, his vital signs were
normal. Body mass index was 21.6kg/m2 (104% ideal body
weight), and his oxyhemoglobin saturation on room air was
96%. No nasal polyposis or sinus tenderness was present.
Pulmonary examination revealed resonance to percussion
and symmetric breath sounds with no wheezing or rales.
Abdominal exam revealed no organomegaly or areas of
tenderness. There was trace digital clubbing. Spirometry
showed a moderate obstructive defect: FVC 5.29L (91%
predicted) and FEV1 2.71L (62% predicted). Chest X-ray
demonstrated signiﬁcant hyperinﬂation and increased linear
markings in the right lower lung zones and perihilar regions
(Figure 1). The results of laboratory measurements of liver
function, fat-soluble vitamin levels, renal function, glucose
and complete blood counts were normal.
3.SubsequentClinicalCourse
The patient had experienced infertility and requested formal
evaluation to ascertain whether having a biological child
with his wife was possible. He was referred to a urologist,
where physical examination revealed atretic vasa deferentia.
The ﬁnding was conﬁrmed on transrectal ultrasound, and
subsequent semen analysis demonstrated azoospermia. He
was aware that he had an unidentiﬁed CFTR mutation
at the time of presentation to our center. As part of a
discussion about family planning, he expressed interest in
more comprehensive genetic testing. Full-sequence CFTR
analysis was performed by Ambry Genetics. The Ambry
Test CF includes a full mutation scan of the CFTR gene
by modiﬁed temporal temperature gradient electrophore-
sis analysis followed by dye-terminator DNA sequencing
of suspect regions. All CFTR exons as well as relevant
intronic regions were ampliﬁed using PCR and proprietary
primers, essentially as described [8]. Testing revealed an
A457P mutation in exon 10 in combination with the F508
deletion. This was the ﬁrst and only time this variant was
observed at Ambry Genetics in over 60,000 chromosomes
analyzed [9]. A literature review and examination of the
Sick Kids Cystic Fibrosis Mutation database revealed no
prior report of the A457P mutation [10]. This mutation is
also not seen in the Clinical and Functional Translation of
CFTR (CFTR2) database, a locus-speciﬁc phenotype-based
database of 40,000 CF patients worldwide [11].
The course of his pulmonary function over time was
reviewed. Between the ages of 17 and 20 years our patient
was actively engaged with a CF center, and his lung function
remained above the national median for his age cohort in
the USA (Figure 2). However, after age 20 years, he was
lost to followup until age 35 years, during which time he
experienced accelerated decline in lung function.
4. Discussion
Although the diagnosis of CF is usually made during early
childhood (70% by age 1 year) [1], late adolescent and adult
diagnosis is increasingly common [2]. Adult patients who
have a delayed diagnosis often present with atypical features
ofthedisease,andamildclinicalpresentationcansometimes
delay diagnosis for years. These patients also tend to have
unusual genotypes that may not be detectable on routine
commercially available mutation panels. Early detection of
diseasemaybeofclinicalbeneﬁt,sincemanyofthesepatients
with mild phenotypes will suﬀer signiﬁcant pulmonary
declineovertime,particularlyifleftuntreated.Asseeninour




























Figure 2: Comparison of lung function of the patient (represented
by FEV1% predicted using the Knudson equation) compared to
median values reported in CF National Registry for patients in 1990
[7].
periods of preserved lung function (Figure 2). We speculate
that the accelerated decline in his lung function, causing it
to approach the national median for CF patients, was due at
least in part to a lack of standard therapy during the 15 years
that he was lost to followup. Though the diagnosis of CF
was made prior to performance of advanced genetic testing
in the case of our patient, the clinical course still illustrates
the importance of implementing uninterrupted CF care for
patients with all presenting CF phenotypes.
The 2008 Cystic Fibrosis Foundation Consensus Report
provided recommendations for the diagnostic process to
be used for patients who present later in life with clinical
features consistent with CF [12]. In addition to these clinical
features, there must be some evidence of CFTR dysfunction.
That can be determined with functional testing (such as
sweat chloride or nasal potential diﬀerence measurement) or
with genetic testing for CFTR mutations. In the case of our
patient, given that he had clinical features (obstructive lung
disease with the presence of CF organisms in the sputum
and obstructive azoospermia) and sweat chloride evidence
of CFTR dysfunction, the diagnosis was established without
needing genetic testing.
Analysis of the previously unidentiﬁed genetic variation
A457P must be considered in the context of its discovery in
anindividualwithanestablisheddiagnosisofCF.Howdowe
interpret this newly discovered mutation? According to one
schema that has recently gained broad acceptance, mutations
in the CFTR gene fall into 1 of 4 categories [3]. They either
are (a) known to cause disease, (b) known not to cause
disease, (c) lie somewhere between these two extremes and
cause disease in some patients but not in others (mutations
ofvariablepenetrance),or(d)haveunknowndiseaseliability
(variants of uncertain clinical signiﬁcance (VUS)). Many
of the mutations with variable penetrance (and some that
cause CF) have also been seen in patients with single organ
system manifestations of CFTR dysfunction but that do not
meet the full diagnostic criteria for CF. These have been
characterizedas“CFTR-relateddisorders”;however,thelines
between a CF-causing mutation and a CFTR-related disease
causing mutation are not absolute [3, 4]. Given that CF is an
autosomalrecessivediseaseandthatourpatientisanaﬀected
individual, it would appear that A457P is a CF-causing
mutation in this instance. Furthermore, this mutation has
not been identiﬁed in screens of the general “healthy” pop-
ulation done in association with the 1000 Genomes or
dbSNP projects [10] and has not been observed in over 1000
individuals undergoing carrier screening suggesting that it is
notacommonvariation[9].GeneticanalysisdonebyAmbry
and other testing companies is proprietary, so the full extent
of sequencing is not always known. Therefore, it is possible,
although unlikely, that another mutation is present on the
A457P chromosome, for example, in an intronic region that
may not have been sequenced. When entered into publicly
available in silico mutation prediction tools PolyPhen [13]
and SIFT [14], the A457P mutation, which resides within
the nucleotide binding domain 1 of the CFTR, was predicted
to be deleterious; however, these methods have not shown
adequatesensitivityorspeciﬁcityinCFtohaveclinicalutility
[15]. Taken together, these ﬁndings argue for A457P being a
disease-causing mutation, though it is still most accurate to
formally categorize it as a VUS.
Mutations in the CFTR gene can also be grouped into
categoriesaccordingtothemechanismbywhichtheydisrupt
CFTR function [4, 16, 17]. Class I mutations result in early
truncation of nascent mRNA and generally lead to severe
disease in homozygotes (or compound heterozygotes with a
Class II mutation). The most common mutation, F508del,
results in a misfolded CFTR (Class II) that is targeted for
degradation within the endoplasmic reticulum. Homozy-
gotes for this defect again generally develop severe disease.
Class III mutations are folded and traﬃcked to the cell
surface but cannot be activated and have no chloride
conductance. Mutations in classes IV–VI all have some level
of chloride channel function. Individuals who carry Class
IV–VI mutations often have milder disease. The relationship
between genotype and pulmonary phenotype is complex and
diﬃcult to predict on an individual basis. However, the
relationship between genotype and pancreatic phenotype is
much stronger, so patients carrying one severe mutation and
one limited mutation (Class IV–VI type) are more likely
to be pancreatic suﬃcient [18]. Our patient’s presentation
of mild respiratory symptoms and pancreatic suﬃciency
in association with one known Class II mutation suggests
that A457P is likely a Class IV–VI mutation (i.e., one that
retains some chloride channel function). Functional testing
could help elucidate the cellular consequences of the A457P
substitution to support the hypothesis that the mutation is
deleterious and to assign the mutation to a functional class;
however, the considerable resources necessary to perform
such conﬁrmatory work would generally make this imprac-
tical for a mutation found in a single patient.
5. Conclusion
We identiﬁed a novel CFTR mutation in a patient who
presented with mild pulmonary symptoms and pancreatic
suﬃciency and who was diagnosed with CF at 16 years of
age. Detailed genetic analysis revealed that he carries the
novelmutation(A457P)alongwiththemostcommonCFTR4 Case Reports in Medicine
mutation (F508del). The novel mutation appears to be
disease causing in this individual but should be regarded
as a VUS until more information can be attained about
its potential to bring about disease in additional patients.
Identiﬁcation and classiﬁcation of novel CFTR mutations
will become increasingly important as more adult patients
with mild clinical presentations and unusual genotypes are
being recognized. By continuing to add to the list of known
disease-causing mutations, our ability to identify patients
withCFwillimproveandweshouldbeabletoprovideearlier
and more comprehensive treatment and genetic counseling.
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